Suppr超能文献

慢性抗凝治疗的非 ST 段抬高型心肌梗死患者的结局:来自全国住院患者样本的观察。

Outcomes among patients with non-ST-elevation myocardial infarction on chronic anticoagulation: Insights from the National Inpatient Sample.

机构信息

Department of Internal Medicine, Riverside Shore Memorial Hospital, Onancock, Virginia, USA.

Department of Cardiology, Ain Shams University, Cairo, Egypt.

出版信息

Catheter Cardiovasc Interv. 2024 Nov;104(5):928-933. doi: 10.1002/ccd.31198. Epub 2024 Aug 27.

Abstract

BACKGROUND

Chronic systemic anticoagulation use is prevalent for various thromboembolic conditions. Anticoagulation (usually through heparin products) is also recommended for the initial management of non-ST-elevation myocardial infarction (NSTEMI).

AIMS

To evaluate the in-hospital outcomes of patients with NSTEMI who have been on chronic anticoagulation.

METHODS

Using the National Inpatient Sample (NIS) years 2016-2020, NSTEMI patients and patients with chronic anticoagulation were identified using the appropriate International Classification of Diseases, 10th version (ICD-10) appropriate codes. The primary outcome was all-cause in-hospital mortality while the secondary outcomes included major bleeding, ischemic cerebrovascular accident (CVA), early percutaneous coronary intervention (PCI) (i.e., within 24 h of admission), coronary artery bypass graft (CABG) during hospitalization, length of stay (LOS), and total charges. Multivariate logistic or linear regression analyses were performed after adjusting for patient-level and hospital-level factors.

RESULTS

Among 2,251,914 adult patients with NSTEMI, 190,540 (8.5%) were on chronic anticoagulation. Chronic anticoagulation use was associated with a lower incidence of in-hospital mortality (adjusted odds ratio [aOR]: 0.69, 95% confidence interval [CI]: 0.65-0.73, p < 0.001). There was no significant difference in major bleeding (aOR: 0.95, 95% CI: 0.88-1.0, p = 0.15) or ischemic CVA (aOR: 0.23, 95% CI: 0.03-1.69, p = 0.15). Chronic anticoagulation use was associated with a lower incidence of early PCI (aOR: 0.78, 95% CI: 0.76-0.80, p < 0.001) and CABG (aOR: 0.43, 95% CI: 0.41-0.45, p < 0.001). Chronic anticoagulation was also associated with decreased LOS and total charges (adjusted mean difference [aMD]: -0.8 days, 95% CI: -0.86 to -0.75, p < 0.001) and (aMD: $-19,340, 95% CI: -20,692 to -17,988, p < 0.001).

CONCLUSIONS

Among patients admitted with NSTEMI, chronic anticoagulation use was associated with lower in-hospital mortality, LOS, and total charges, with no difference in the incidence of major bleeding.

摘要

背景

慢性全身性抗凝治疗在各种血栓栓塞性疾病中很常见。对于非 ST 段抬高型心肌梗死(NSTEMI),也推荐使用抗凝治疗(通常通过肝素类产品)进行初始治疗。

目的

评估正在接受慢性抗凝治疗的 NSTEMI 患者的住院期间结局。

方法

使用国家住院患者样本(NIS)2016-2020 年的数据,使用适当的国际疾病分类,第 10 版(ICD-10)适当的代码,确定 NSTEMI 患者和慢性抗凝治疗患者。主要结局是全因住院期间死亡率,次要结局包括主要出血、缺血性脑血管意外(CVA)、早期经皮冠状动脉介入治疗(PCI)(即入院后 24 小时内)、住院期间冠状动脉旁路移植术(CABG)、住院时间(LOS)和总费用。在调整了患者水平和医院水平的因素后,进行了多变量逻辑或线性回归分析。

结果

在 2251914 名成年 NSTEMI 患者中,有 190540 名(8.5%)正在接受慢性抗凝治疗。慢性抗凝治疗与较低的住院期间死亡率相关(调整后的优势比[aOR]:0.69,95%置信区间[CI]:0.65-0.73,p<0.001)。主要出血(aOR:0.95,95%CI:0.88-1.0,p=0.15)或缺血性 CVA(aOR:0.23,95%CI:0.03-1.69,p=0.15)发生率无显著差异。慢性抗凝治疗与较低的早期 PCI(aOR:0.78,95%CI:0.76-0.80,p<0.001)和 CABG(aOR:0.43,95%CI:0.41-0.45,p<0.001)发生率相关。慢性抗凝治疗还与 LOS 和总费用的减少相关(调整后的平均差值[aMD]:-0.8 天,95%CI:-0.86 至-0.75,p<0.001)和(aMD:-19340 美元,95%CI:-20692 美元至-17988 美元,p<0.001)。

结论

在因 NSTEMI 住院的患者中,慢性抗凝治疗与较低的住院期间死亡率、LOS 和总费用相关,主要出血发生率无差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验